Publications by authors named "M Panagopoulou"
Article Synopsis
- BRCA1 and BRCA2 are tumor suppressor genes critical for repairing DNA damage through the Homologous Recombination pathway, and mutations in these genes are linked to higher risks of breast and ovarian cancers.
- Methylation of BRCA1/2 promoters can create a "BRCAness" phenotype, indicating HR deficiency in tumors, even when BRCA mutations are absent, and this methylation may serve as a valuable biomarker for predicting responsiveness to therapies like PARP inhibitors.
- The review emphasizes the need for further research into BRCA1/2 methylation as a predictive tool in cancer treatment, suggesting it could significantly enhance prognosis and treatment strategies across various cancer types.
Article Synopsis
- * The study introduced a machine learning (AutoML) approach to analyze DNA methylation data, leading to the identification of SCZ-specific biomarkers such as IGF2BP1, CENPI, and PSME4 from blood samples of SCZ patients compared to healthy controls.
- * An optimized five-feature biosignature was developed that included gene methylation levels and demographic factors, showing promise for being used in clinical diagnostics for SCZ, with a notable performance accuracy.
Article Synopsis
- Circulating cell-free DNA (ccfDNA) of mitochondrial origin (ccf-mtDNA) is a small part of the total ccfDNA in bodily fluids, with abnormal levels linked to various diseases.
- A new standardized dual-qPCR assay effectively measures nuclear and mitochondrial ccfDNA, revealing that high ccf-mtDNA levels are significant in Breast Cancer and Type 2 Diabetes, but not in Osteoarthritis.
- Machine learning was applied to create biosignatures for diagnosing and predicting outcomes in these diseases, highlighting their potential in improving clinical management.
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malignancies. ISB 1442 consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity-induced blocking of proximal CD47 receptors on the same cell while preventing on-target off-tumor binding on healthy cells.
View Article and Find Full Text PDFArticle Synopsis
- Circulating cell-free DNA (ccfDNA) shows promise as a biomarker for precision medicine diagnostics, leading researchers to explore its structure and biology.
- Raman spectroscopy was used to analyze ccfDNA from various sources, revealing distinct chemical profiles related to health conditions like cancer and diabetes.
- The study suggests that Raman spectroscopy could enhance liquid biopsy diagnostics, offering valuable insights into the biomolecular structure of ccfDNA in both healthy individuals and patients.